ID   D-247MG
AC   CVCL_1153
SY   D-247 MG; D-247-MG; D247MG
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   Cell_Model_Passport; SIDM00622
DR   ChEMBL-Cells; CHEMBL3308542
DR   ChEMBL-Targets; CHEMBL2366237
DR   Cosmic; 849881
DR   Cosmic; 946367
DR   Cosmic; 2367513
DR   Cosmic-CLP; 946367
DR   DepMap; ACH-002224
DR   GDSC; 946367
DR   GEO; GSM1669715
DR   IARC_TP53; 27689
DR   PharmacoDB; D247MG_271_2019
DR   Wikidata; Q54817124
RX   PubMed=2881426;
RX   PubMed=3675803;
RX   PubMed=9220028;
RX   PubMed=10416987;
RX   PubMed=11351043;
RX   PubMed=14614447;
RX   PubMed=20164919;
RX   PubMed=22570425;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for PTEN c.210-1G>C; splice acceptor mutation (CCLE; Cosmic-CLP).
CC   Sequence variation: Has no TP53 mutation (PubMed=14614447).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.5%; East Asian, North=0%; East Asian, South=0%; South Asian=1.46%; European, North=67.83%; European, South=30.2% (PubMed=30894373).
CC   Misspelling: D24.7; In PubMed=11351043.
ST   Source(s): Cosmic-CLP; PubMed=22570425
ST   Amelogenin: X
ST   CSF1PO: 9,11
ST   D13S317: 8,10
ST   D16S539: 9,12
ST   D18S51: 15,17
ST   D21S11: 30
ST   D3S1358: 17,18
ST   D5S818: 10,12
ST   D7S820: 9,13
ST   D8S1179: 15
ST   FGA: 24,27
ST   Penta D: 11,12
ST   Penta E: 13,18
ST   TH01: 6,9
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C3796; Gliosarcoma
DI   ORDO; Orphanet_251576; Gliosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 25
RX   PubMed=2881426; DOI=10.1007/BF00687952;
RA   Bigner S.H., Friedman H.S., Biegel J.A., Wikstrand C.J., Mark J.,
RA   Gebhardt R., Eng L.F., Bigner D.D.;
RT   "Specific chromosomal abnormalities characterize four established cell
RT   lines derived from malignant human gliomas.";
RL   Acta Neuropathol. 72:86-97(1986).
RX   PubMed=3675803;
RA   Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.;
RT   "DNA content and chromosomes in permanent cultured cell lines derived
RT   from malignant human gliomas.";
RL   Anal. Quant. Cytol. Histol. 9:435-444(1987).
RX   PubMed=9220028; DOI=10.1016/S0303-7207(97)00080-4;
RA   Sharif T.R., Luo W., Sharif M.;
RT   "Functional expression of bombesin receptor in most adult and
RT   pediatric human glioblastoma cell lines; role in mitogenesis and in
RT   stimulating the mitogen-activated protein kinase pathway.";
RL   Mol. Cell. Endocrinol. 130:119-130(1997).
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
RX   PubMed=11351043; DOI=10.1038/labinvest.3780280;
RA   Hui A.B.-Y., Lo K.-W., Yin X.-L., Poon W.-S., Ng H.-K.;
RT   "Detection of multiple gene amplifications in glioblastoma multiforme
RT   using array-based comparative genomic hybridization.";
RL   Lab. Invest. 81:717-723(2001).
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).